Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
AbbVie is conducting a clinical study titled SELECT-SLE to evaluate the safety and efficacy of upadacitinib in adults with moderately to severely active Systemic Lupus Erythematosus (SLE). The study aims to assess adverse events and changes in disease activity, providing significant insights into the treatment of this immune-mediated disease.
The intervention being tested is upadacitinib, an oral tablet already approved for other autoimmune conditions like rheumatoid arthritis. It is being tested against a placebo to determine its effectiveness in treating SLE.
The study is interventional, randomized, and uses a sequential model with quadruple masking. Its primary purpose is treatment, ensuring unbiased results through a double-blind approach.
The study began on July 19, 2023, with primary completion expected by mid-2025. The last update was submitted on June 25, 2025, indicating ongoing progress.
This study could potentially impact AbbVie’s market position by expanding the use of upadacitinib, possibly boosting investor confidence. It also highlights AbbVie’s competitive edge in the autoimmune treatment market.
The study is currently recruiting, with further details available on the ClinicalTrials portal.